2022
DOI: 10.21203/rs.3.rs-2273397/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Denosumab for Osteoporosis in Patients With Primary Hyperparathyroidism and Renal Insufficiency

Abstract: Primary hyperparathyroidism (PHPT) is characterized by hypercalcemia. The only curative treatment is parathyroidectomy. However, patients are often ineligible or decline surgery. Denosumab (Dmab) is an antiresorptive pharmaceutical alternative. The effects of exposure to Dmab in subjects with chronic kidney disease (CKD) and PHPT are unknown. Purpose:We aimed to assess the efficacy and safety of denosumab in postmenopausal women with PHPT- related osteoporosis and CKD. Methods: Women over 50 years of age wit… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 52 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?